John A. Orwin
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TRAX Announces $200M Private Placement and Analyst Upgrades. First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Transaction History
| ANAB | ▲ Buy | Option Exercise | 1,300 | $0 | 9/15/2026 | View on chart |
| TRAX | ▲ Buy | Option Exercise | 1,300 | $0 | 9/15/2026 | View on chart |
| TRAX | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 1,300 | $0 | 9/15/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 1,300 | $0 | 9/15/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 2,035 | $0 | 6/15/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks
Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.